• Facebook
  • Twitter
  • Instagram
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
MYELOMA360
  • Home
  • News
  • Education
    • Conference Coverage
      • ASCO & EHA 2019
      • EHA 2018
      • ASH 2017
    • CME & Webcasts
  • Events
  • Resources
    • Practice Resources
    • Patient Information
      • Product Education
      • Books
  • Videos
Select Page
Interesting Myeloma Articles September 2021

Interesting Myeloma Articles September 2021

by MM360 Staff | Sep 28, 2021 | Featured News, Myeloma News

Here are some interesting Myeloma journal articles and some of the most discussed on Twitter for September 2021. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score...

Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News

People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and poorer survival outcomes, a study found. The study, “Effect of the ABO blood groups on the development, clinical...

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News

The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior therapies, and who failed to respond to at least one...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

by MM360 Staff | Apr 21, 2021 | Featured, Webinars

Downloadable Slide Set In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient’s perspective on treatment options. Learners will also get a look ahead at emerging therapeutic...
Best Treatment for Newly Diagnosed Multiple Myeloma

Best Treatment for Newly Diagnosed Multiple Myeloma

by MM360 Staff | Apr 2, 2021 | Featured News, Myeloma News

A recent article published in JAMA Oncology1 questions whether VRd should remain as the standard of care (SOC) in newly diagnosed multiple myeloma. Careful analysis of the ENDURANCE (E1A11) phase III trial2 raises the question whether VRd continues to be the SOC for...
« Older Entries

Recent Content

  • Racial Disparities Seen in US Food and Drug Administration Drug Approval Trials in Multiple Myeloma
  • Sarclisa Combination Shows Positive Results in Patients With Relapsed Multiple Myeloma
  • Trial Kicks Off to Study Experimental CAR-T Cell Therapy in Myeloma
  • Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma
  • The Heparanase/Syndecan-1 Axis in Cancer Progression
  • Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
  • Computational and Mechanistic Study of the Therapeutic Potential of Compound Formononetin in Preventing Mast Cell Activation and IgE Production in Food Anaphylaxis
  • Transcriptome and regulome signatures of multiple myeloma induced by bone marrow stromal cells
  • One-Year Comparison of Body Composition in a Cohort of Patients with Multiple Myeloma
  • Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
  • Facebook
  • Twitter
  • Instagram
©2016-2021 MYELOMA360 & MindWrap Medical, LLC